Study Summary
The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer.
Want to learn more about this trial?
Request More InfoInterventions
Anti-MUC1 CAR-T cellsBIOLOGICAL
Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
PD-1 knockout Engineered T cellsBIOLOGICAL
Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.
CAR-T combined with PD-1 Knockout T cellsCOMBINATION_PRODUCT
Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| First Affiliated Hospital of Guangdong Pharmaceutical University | Guangzhou | Guangdong | China |
| Professor Size Chen | Guangzhou | Guangdong | China |